{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-015276","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.906751+00:00","generated_at":"2026-06-28T10:30:43.099702+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Omeros Q3 OMIDRIA rev $30M (+4.1% QoQ); net loss narrows; FDA CRL for narsoplimab","bullets":["OMIDRIA revenue $30.0M in Q3, up 4.1% from Q2 $28.8M; driven by ASC growth.","Net loss $22.7M ($0.36/sh) improved from $28.6M ($0.46/sh) in Q2; cash $50.4M.","CMS confirmed separate payment for OMIDRIA in ASC for 2022; NOPAIN Act has 34 Senate/74 House sponsors.","Received FDA Complete Response Letter for narsoplimab BLA in HSCT-TMA; preparing Type A meeting.","Phase 1 data for OMS906 shows high alternative pathway suppression; moving directly into PNH patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-015276","json":"https://secwatch.observer/filing/0001558370-21-015276.json","markdown":"https://secwatch.observer/filing/0001558370-21-015276.md","text":"https://secwatch.observer/filing/0001558370-21-015276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000155837021015276/0001558370-21-015276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000155837021015276/omer-20211109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:30:43.099702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}